Targeting cancer with power and precision


Sesen Bio, Inc. (NASDAQ: SESN), previously Eleven Biotherapeutics, Inc., is a late-stage company developing next-generation antibody-drug conjugate (ADC) therapies for patients with cancer. Their approach aims to overcome limitations of traditional ADCs by incorporating a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule designed to selectively, effectively and broadly kill cancer cells while sparing healthy cells. These single protein molecules are known as fusion proteins. Their lead program, Vicinium™, is a novel fusion protein currently in Phase 3 development for the treatment of patients with non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin (BCG).


Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.sesenbio.com

Recent News

January 3, 2019
Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer

December 27, 2018
Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer

December 3, 2018
Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer

Read More News

Associated Team Members

Cary Pfeffer, M.D.
Partner

Abbie Celniker, Ph.D.
Partner